Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Humoral and cellular response to the third COVID-19 vaccination in patients with inborn errors of immunity or mannose-binding lectin deficiency : A prospective controlled open-label trial.
Vossen MG, Kartnig F, Mrak D, Simader E, Stiasny K, Kain R, Perkmann T, Haslacher H, Aberle JH, Heinz LX, Sieghart D, Burgmann H, Aletaha D, Scheinecker C, Bonelli M, Göschl L. Vossen MG, et al. Among authors: mrak d. Wien Klin Wochenschr. 2024 Nov;136(21-22):598-607. doi: 10.1007/s00508-024-02459-6. Epub 2024 Oct 24. Wien Klin Wochenschr. 2024. PMID: 39446203 Free PMC article. Clinical Trial.
FAPi PET/CT for assessment and visualisation of active myositis-related interstitial lung disease: a prospective observational pilot study.
Kastrati K, Nakuz TS, Kulterer OC, Geßl I, Simader E, Mrak D, Bonelli M, Kiener HP, Prayer F, Prosch H, Aletaha D, Langsteger W, Traub-Weidinger T, Blüml S, Lechner-Radner H, Hacker M, Mandl P. Kastrati K, et al. Among authors: mrak d. EClinicalMedicine. 2024 Apr 10;72:102598. doi: 10.1016/j.eclinm.2024.102598. eCollection 2024 Jun. EClinicalMedicine. 2024. PMID: 38633577 Free PMC article.
Impact of muscle biopsy on the clinical decision-making process in patients with suspected idiopathic inflammatory myopathy.
Kastrati K, Nakhost Lotfi N, Tawfik MG, Gelpi E, Hametner S, Höftberger R, Zimprich F, Cetin H, Lindeck-Pozza E, Heil PM, Kiener HP, Heinz LX, Mrak D, Aletaha D, Bonelli M, Radner H. Kastrati K, et al. Among authors: mrak d. J Autoimmun. 2024 Apr;144:103185. doi: 10.1016/j.jaut.2024.103185. Epub 2024 Mar 1. J Autoimmun. 2024. PMID: 38428109 Free article.
Accelerated waning of immune responses to a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases.
Mrak D, Kartnig F, Sieghart D, Simader E, Radner H, Mandl P, Göschl L, Hofer P, Deimel T, Gessl I, Kain R, Winkler S, Smolen JS, Perkmann T, Haslacher H, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. J Autoimmun. 2023 Feb;135:102981. doi: 10.1016/j.jaut.2022.102981. Epub 2022 Dec 22. J Autoimmun. 2023. PMID: 36706534 Free PMC article.
Multiparametric Prediction Models for Coronavirus Disease 2019 Vaccine Selection: Results of a Comparative Population-Based Cohort Study.
Sieghart D, Hana CA, Haslacher H, Perkmann T, Heinz LX, Fedrizzi C, Anderle K, Wiedermann U, Condur I, Drapalik S, Steinbrecher H, Mrak D, Mucher P, Hasenoehrl T, Zrdavkovic A, Wagner B, Palma S, Jordakieva G, Jorda A, Firbas C, Wagner A, Haiden N, Bergmann F, Crevenna R, Zeitlinger M, Bonelli M, Aletaha D, Radner H. Sieghart D, et al. Among authors: mrak d. Clin Infect Dis. 2023 Mar 4;76(5):816-823. doi: 10.1093/cid/ciac840. Clin Infect Dis. 2023. PMID: 36328594
Reactogenicity and immunogenicity of the second COVID-19 vaccination in patients with inborn errors of immunity or mannan-binding lectin deficiency.
Göschl L, Mrak D, Grabmeier-Pfistershammer K, Stiasny K, Haslacher H, Schneider L, Deimel T, Kartnig F, Tobudic S, Aletaha D, Burgmann H, Bonelli M, Pickl WF, Förster-Waldl E, Scheinecker C, Vossen MG. Göschl L, et al. Among authors: mrak d. Front Immunol. 2022 Sep 14;13:974987. doi: 10.3389/fimmu.2022.974987. eCollection 2022. Front Immunol. 2022. PMID: 36189225 Free PMC article.
Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls.
Kartnig F, Mrak D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Hommer N, Mayer M, Hofer P, Hummel T, Deimel T, Geßl I, Puchner A, Kerschbaumer A, Thalhammer R, Handisurya A, Kain R, Winkler S, Smolen JS, Stiasny K, Perkmann T, Haslacher H, Aberle JH, Aletaha D, Heinz LX, Sieghart D, Bonelli M. Kartnig F, et al. Among authors: mrak d. Ann Rheum Dis. 2023 Feb;82(2):292-300. doi: 10.1136/ard-2022-222682. Epub 2022 Sep 15. Ann Rheum Dis. 2023. PMID: 36109141 Clinical Trial.
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial.
Mrak D, Sieghart D, Simader E, Tobudic S, Radner H, Mandl P, Göschl L, Koblischke M, Hommer N, Wagner A, Mayer M, Schubert L, Hartl L, Kozbial K, Hofer P, Kartnig F, Hummel T, Kerschbaumer A, Deimel T, Puchner A, Gudipati V, Thalhammer R, Munda P, Uyanik-Ünal K, Zuckermann A, Novacek G, Reiberger T, Garner-Spitzer E, Reindl-Schwaighofer R, Kain R, Winkler S, Smolen JS, Stiasny K, Fischer GF, Perkmann T, Haslacher H, Zeitlinger M, Wiedermann U, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Nat Commun. 2022 Sep 12;13(1):5362. doi: 10.1038/s41467-022-33036-y. Nat Commun. 2022. PMID: 36097029 Free PMC article. Clinical Trial.
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study.
Mrak D, Simader E, Sieghart D, Mandl P, Radner H, Perkmann T, Haslacher H, Mayer M, Koblischke M, Hofer P, Göschl L, Kartnig F, Deimel T, Kerschbaumer A, Hummel T, Kornek B, Thalhammer R, Stiasny K, Winkler S, Smolen JS, Aberle JH, Aletaha D, Heinz LX, Bonelli M. Mrak D, et al. Ann Rheum Dis. 2022 Dec;81(12):1750-1756. doi: 10.1136/ard-2022-222579. Epub 2022 Aug 17. Ann Rheum Dis. 2022. PMID: 35977809
19 results